FLORENCE, Ky., Sept. 21, 2011 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD) the world's leading research and production firm specializing in immune system support compounds based on Beta Glucan derived from baker's yeast, announced today that it has appointed Jim Roufs as Director of Product Development. Mr. Roufs brings more than twenty years of industry experience in the dietary supplement field to augment Immudyne's research and production team. He previously led New Product Development for more than seven years for the world's largest dietary supplement brand, where he participated in developing and launching numerous products with multimillion dollar annual revenues. Mr. Roufs activities will be focused on food and beverage applications for Immudyne's premier Beta Glucan product, as well as dietary supplements for immune system support and athlete training aids.
Mr. Roufs has headed up product development at other leading companies in the dietary supplement industry, has several publications in both scientific journals and lay press, and is a patent holder. He is a Registered Dietitian, holds a Masters degree in Food Science/Nutrition from California Polytechnic State University, as well as having taught Nutrition at Loyola Marymount University.
Roufs commented, "In my previous position, I had the opportunity to review nearly every immune modulating product available. I believe Immudyne's product is the best, not only because of the amount of patent protection and other secret proprietary know how which Immudyne controls, but more importantly our products have the lowest clinically effective dose I have seen. In fact, just 15 mg a day has been shown to extend the lifespan of terminally ill cancer patients with 65% still being alive after 3 months vs just 4% in a similar control group. And just 7.5 mg per day completely eliminated the reoccurrence in cancer patients in remission over a 15-month period vs a 22% reoccurrence in the matched control group. Yet even though these were quite impressive results which have been published, no one is allowed to make cancer claims on a dietary supplement. Thus, we are in the process of obtaining clinical data that are compliant with FDA's structure/function claims and we look forward to continuing to help build the science behind the product, a process which I believe is integral to significantly growing the business. I am excited to be part of the Immudyne team and look forward to expanding sales throughout the world."
Mark McLaughlin, CEO of Immudyne stated, "The addition of Jim Roufs to our team is a big first step in focusing our resources and organization on leveraging our intellectual property and production expertise to capture significant revenues in the nutritional supplement and food and beverage fields. In the past few years we successfully defended our patents, significantly elevated our production processes, and established an improved corporate infrastructure, all of which have positioned Immudyne to successfully focus our efforts on marketing and growth."
About Immudyne
Immudyne manufactures, distributes and sells patented and proprietary all-natural yeast beta glucan products for immune system support.
Immudyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.globenewswire.com/newsroom/ctr%3Fd=216160%26l=7%26a=www.immudyne.com%26u=http%253A%252F%252Fwww.immudyne.com" target="_blank">www.immudyne.com (currently being transformed.) Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates,""believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.